Special to WorldTribune.com

By Willy Lam, East-Asia-Intel.com

The high-profile exposure of alleged corruption practices by the China division of pharmaceutical giant GlaxoSmithKline (GSK) indicates that Beijing’s anti-graft campaign has entered a new level.

That official mouthpieces such as CCTV, People’s Daily and Global Times have come out with bitter attacks against GSK, however, suggests that politics has again intervened in what should primarily be a judicial procedure.

After all, the four senior officials of GSK, who have been accused of offering multi-million yuan bribes to doctors and hospital administers to boost the company’s sales, are not expected to appear in court for at least a few months.

Moreover, it is well-known that both foreign and domestic Chinese firms in the fast-growing health sector have for the past two decades offered voluminous kickbacks and other benefits to medical practitioners. Similar corruption practices are also found in fields ranging from education to insurance.

See complete article.

  GlaxoSmithKline, Li Keqiang, Why Beijing is targeting multinationals in new phase of the anti-corruption campaign, Xi Jinping